Mood stabilizers during breastfeeding: a systematic review of the recent literature

Basit Öğe Kaydı
dc.contributor.authorUguz, Faruk
dc.contributor.authorSharma, Verinder
dc.date.accessioned2024-02-23T14:24:02Z
dc.date.available2024-02-23T14:24:02Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractObjectiveThis review examined the safety of mood stabilizers in exposed breastfed infants. MethodsPubMed was searched for English language reports between 1 January 1995 and 30 August 2015 by using combinations of key words breastfeeding, lactation, postpartum period, puerperium, mood stabilizers, lithium, lamotrigine, valproate, carbamazepine, and oxcarbazepine. Case reports, case series, and prospective or cross-sectional studies including relevant data such as relative infant dose, milk-to-plasma ratio, infant drug plasma levels, and adverse events were identified. ResultsA total of 26 of 604 relevant reports in PubMed were included in the study. These reports included lamotrigine (122 cases in 12 reports), lithium (26 cases in five reports), carbamazepine (64 cases in five reports), valproate (nine cases in three reports), and oxcarbazepine (two cases in two reports). Of 26 reports, one report included both carbamazepine and valproate. The reports suggest that a considerable amount of lithium and lamotrigine are excreted into breast milk. There is a paucity of data on valproate and oxcarbazepine; however, the infant/maternal ratio of serum drug concentration seems to be lower in valproate exposure compared to other mood stabilizers. The incidence of adverse events in infants exposed to mood stabilizers is reported to be very low. ConclusionsThe current data suggest that mood stabilizers can be prescribed without any adverse events in most infants in lactating women. The available reports also suggest a low prevalence rate of laboratory abnormalities including hepatic, kidney, and thyroid functions in the infants. Additional studies examining short-term and especially long-term effects of mood stabilizers on breastfed infants are required.en_US
dc.identifier.doi10.1111/bdi.12398
dc.identifier.endpage333en_US
dc.identifier.issn1398-5647
dc.identifier.issn1399-5618
dc.identifier.issue4en_US
dc.identifier.pmid27297617en_US
dc.identifier.scopus2-s2.0-84976608577en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage325en_US
dc.identifier.urihttps://doi.org/10.1111/bdi.12398
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13793
dc.identifier.volume18en_US
dc.identifier.wosWOS:000379697800002en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofBipolar Disordersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBreastfeedingen_US
dc.subjectLactationen_US
dc.subjectMood Stabilizersen_US
dc.subjectPostpartumen_US
dc.titleMood stabilizers during breastfeeding: a systematic review of the recent literatureen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu